(PDF) Cost-Effectiveness of First-Line Therapy for Advanced

Cost-Effectiveness of First-Line Therapy for Advanced Non-Small Cell Lung Cancer (Nsclc)

Value in Health - United Kingdom

doi 10.1016/j.jval.2014.08.110

Full Text

Abstract

Available in full text

Categories

Occupational Health

Date

November 1, 2014

Authors

Publisher

Elsevier BV

Related search

Cost-Effectiveness of First-Line Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer Unsuitable for Chemotherapy

English

Cost-Effectiveness of ALK Testing and First-Line Crizotinib Therapy for Non-Small-Cell Lung Cancer in China

Multidisciplinary

English

PCN37 Cost-Minimization Analysis of Second-Line Chemotherapy for Non-Small-Cell Lung Cancer (NSCLC)

Value in Health

Occupational Health

English

Pcn152 - Cost Effectiveness of Alectinib in the First Line Treatment of Advanced Alk-Positive Non-Small Cell Lung Cancer in Turkey

Value in Health

Occupational Health

English

P3.04-17 Cost-Effectiveness of Atezolizumab for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) in Canada

Journal of Thoracic Oncology

Respiratory Medicine

English

Redefining Treatment Paradigms in First-Line Advanced Non-Small Cell Lung Cancer

Clinical Cancer Research

Cancer Research

English

TG4010 Immunotherapy Combined With First-Line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC): Phase IIb Results of the TIME Study

Journal for ImmunoTherapy of Cancer

Molecular Medicine

Cancer Research

English

Effectiveness of First-Line Treatments in Metastatic Squamous Non-Small-Cell Lung Cancer

Current Oncology

English

Cost Effectiveness of Treatment With New Agents in Advanced Non-Small-Cell Lung Cancer

PharmacoEconomics

Occupational Health

English